MedDevicePro – Medical Device Regulatory Intelligence

🚨 Multi-Jurisdiction Device Approval Is Getting Harder

Getting a medical device to market is one of the most complex regulatory challenges in any industry. The wrong pathway assumption doesn't just slow you down — it can cost a year and a failed submission.

🔊 VO-01

4

major jurisdictions with independent classification systems

12

submission pathways across US, EU, Canada, GCC

365+

days for a PMA or CE Mark — if the strategy is right

135K+

verified regulatory document chunks with cryptographic proof

⚠️

Wrong Pathway = Wasted Year

The difference between a 510(k) and a De Novo isn't just paperwork — it's six to twelve months and potentially millions in clinical study costs. One wrong assumption about pathway eligibility resets the clock.

📋

Evidence Gaps Found Late Are Expensive

The most common reason a submission fails or gets delayed isn't a paperwork problem — it's a clinical evidence gap that wasn't identified until the review clock was already running.

🇪🇺

EU MDR Caught Manufacturers Off Guard

Devices with CE marks for decades suddenly faced entirely new clinical evidence requirements under MDR 2017/745. Companies that didn't see it coming are still catching up — and the EUDAMED transition in May 2026 is next.

🌍

Four Jurisdictions, Four Classification Systems

FDA, EU MDR, Health Canada, and GCC each have independent classification rules, submission requirements, and evidence standards. A strategy built on one jurisdiction's logic does not transfer to the others.

⚙️ Three-Layer Architecture for Defensible Answers

MedDevicePro is built on TV-GRAG v2.1 — a three-layer architecture that makes every answer auditable, every citation cryptographically verifiable, and every response traceable back to the exact regulatory source that was used.

🔊VO-02

Layer 1 — Vector Database (Mandatory for Every Query)

Qdrant Vector DB

135,000+ document chunks
SHA-256 hash · Effective date · Source URL

→

Every query — even simple lookups — must pass through Qdrant. This is what provides cryptographic proof of the exact document version used, the legal effective date, and a verifiable source URL for every answer.

Layer 2 — Knowledge Graph (Entity Reference Store)

Neo4j Graph

114,000+ nodes · 56,000+ relationships
Devices → Classifications → Pathways → Evidence

→

Answers structural queries in under 100ms and routes complex queries to the appropriate specialized model. Stores references to Qdrant source documents — not duplicate content.

Layer 3 — Four-Model Consensus System

Pathway Navigator

Classification & routing

Evidence Analyst

Clinical requirements

Executive Synthesis

Timelines & summaries

Validator

Fact-checking · Hallucination detection

Graph-Only Path (~40% of Queries)

Device classifications, pathway lookups, predicate searches. Neo4j traversal delivers the answer in under 100ms with mandatory Qdrant provenance fetch. Zero model inference — deterministic, fast, auditable.

Model Synthesis Path (~60% of Queries)

Complex pathway guidance, evidence gap analysis, timeline predictions, multi-jurisdiction comparisons. Neo4j identifies relevant entities, Qdrant fetches context and provenance, four-model consensus produces the answer.

Every Response Includes

Document hash (SHA-256), effective date, validation status, source URL, models used, confidence level, inference path. Complete audit payload — not added afterward, required by the architecture.

150,000+ Training Completions

Each specialized model is trained on its task type: 20,000 pathway determination examples, 20,000 clinical evidence mappings, 20,000 timeline estimations, 25,000 fact-checking examples.

🔬 Multi-Jurisdiction Classification Engine

Before you can determine a regulatory pathway, you need to know what class your device is in — and that answer is different in every jurisdiction. Getting it wrong means your entire pathway strategy is built on a flawed foundation.

🔊VO-03

Jurisdiction	Classes	Authority	Regulation	Classification Basis
🇺🇸 United States	IIIIII	FDA CDRH	21 CFR 860–898	Risk level, intended use, device type panel
🇪🇺 European Union	IIIaIIbIII	Notified Bodies	MDR 2017/745 Annex VIII	18 classification rules, invasiveness, duration
🇨🇦 Canada	IIIIIIIV	Health Canada	SOR/98-282 CMDR	Risk-based, contact duration, body interaction
🇸🇦 Saudi Arabia	ABCD	SFDA	SFDA MedDev Regulations	Risk-based, 4-class system
🇦🇪 UAE	Risk-Based	MOHAP	MOHAP MedDev Regulations	Risk-based classification framework

Classification Inputs

Intended use (diagnostic, therapeutic, monitoring), invasive or implantable status, active device or software component, connectivity, sterile, measuring function, duration of contact (temporary, short-term, long-term, permanent), body system interaction.

Parallel Output Across All Jurisdictions

A single device description returns the classification result for all active jurisdictions simultaneously — including the specific regulatory rule that generated each result and a cryptographically verified source citation for each.

Automatic Pathway Assignment

Classification result automatically maps to available submission pathways in each jurisdiction. You're not just getting a class designation — you're getting the strategic starting point for your entire market access plan.

Class Mapping Across Jurisdictions

Class II in the US maps approximately to IIa or IIb in EU MDR — but the evidence requirements diverge significantly. The system surfaces these mapping nuances and flags where harmonization opportunities exist and where they don't.

🗺️ Twelve Submission Pathways Across Four Jurisdictions

Choosing the wrong regulatory pathway is one of the most expensive mistakes a device manufacturer can make. MedDevicePro maps all twelve routes — eligibility criteria, timelines, clinical data requirements, and the strategic tradeoffs between them.

🔊VO-04

Pathway	Jurisdiction	Typical Timeline	Clinical Data	Predicate Required
510(k)	US FDA	90–130 days	Variable	✅ Required
De Novo	US FDA	150+ days	Required	❌ Novel device
PMA	US FDA	365+ days	Full clinical trials	❌ Not applicable
HDE	US FDA	Variable	Limited	❌ Humanitarian use
CE Mark (Notified Body)	EU MDR	365+ days	Required per MDR	❌ Not applicable
CE Mark (Self-Declaration)	EU MDR	Variable	Required per MDR	❌ Class I only
Medical Device Licence (MDL)	Canada	60–90 days	Per classification	Conditional
SFDA Approval	Saudi Arabia	60–120 days	Per classification	❌ Not applicable
MOHAP Registration	UAE	Variable	Per classification	❌ Not applicable
UKCA	UK	Variable	Post-Brexit requirements	❌ Not applicable
TGA	Australia	60–120 days	Per classification	❌ Not applicable
ANVISA	Brazil	Variable	Per classification	❌ Not applicable

Pathway Eligibility, Not Just Existence

MedDevicePro doesn't just list pathways — it maps which routes your specific device qualifies for, where the eligibility decision points are, and what the evidence requirements look like for each option.

Post-Approval Change Management

Change notification requirements, substantial versus non-substantial change determination, amendment procedures, and the specific timeline and submission implications of each change type — across all four jurisdictions.

🧪 Clinical Evidence Gap Analyzer

The single most common reason a submission fails or gets delayed is a clinical evidence gap that wasn't identified until the review clock was running. MedDevicePro finds those gaps before you submit.

🔊VO-05

🇺🇸 510(k) — Substantial Equivalence

Predicate device selection and justification logic

Equivalence statement: intended use + technological characteristics

Performance testing: bench, biocompatibility, software

Clinical data requirements: comparative studies, literature, or non-clinical pathway

Predicate chain analysis up to 3 generations

🇺🇸 PMA — Class III Devices

IDE Phase II/III clinical trials (typically 100+ subjects)

Primary endpoint clinical data requirements

Comparator device selection

Safety and effectiveness assessment structure

Post-approval surveillance plan requirements

🇪🇺 EU MDR — CE Mark

Technical documentation per ISO 14971 risk management

Clinical data package: literature + investigations per Rule 22

Clinical Evaluation Report structure

Post-market surveillance per Article 80

Periodic Safety Update Report (PSUR) obligations

Specific Endpoints for Your Device Category

Not a generic checklist. The analyzer identifies the specific endpoints required: MARD for glucose monitors, Sensitivity and Specificity for diagnostics, Cohen's Kappa for agreement studies. Requirements are device-category specific, not pathway-generic.

Study Design Recommendations

Prospective, RCT, or real-world evidence — the appropriate study design for your device category, pathway, and jurisdiction. Including biocompatibility testing requirements under ISO 10993 and software validation under IEC 62304.

Completed vs. Gap Mapping

The output maps what you have against what's required — not as a static checklist but as a live gap analysis. Evidence gaps found now cost time. Evidence gaps found by a reviewer cost far more.

Historical Data: 54,000+ Real Approvals

Timeline predictions draw on 40,000+ FDA 510(k) clearances, 5,000+ PMAs, and Health Canada MDL approvals. Median days, range, confidence interval, and comparison to official FDA targets — statistical predictions, not rules-based guesses.

💬 Live Query Example: CGM Market Access Strategy

An illustration of the kind of query MedDevicePro answers in seconds — and what that answer actually looks like, including the audit trail that makes it defensible.

🔊VO-06

💬 Regulatory Affairs Team — Market Access Strategy Query

What class is a continuous glucose monitor in the US and Canada, and what are the available pathways?

US (FDA)

Class II under 21 CFR 862.1355 — Continuous glucose monitor
Primary pathway: 510(k) with predicate device · Typical timeline: 90–130 days
Predicate chain available · 40,000+ FDA clearance records searched

Canada (HC)

Class III under SOR/98-282, Schedule 1, Part 2
Pathway: Class III Medical Device Licence · Typical timeline: 60–90 days
Clinical evidence required · US clearance does not automatically satisfy HC clinical evidence requirements for Class III

Strategy Note

Class mapping divergence flagged: US Class II does not map directly to Canadian Class II for this device type. Sequential strategy recommended: FDA 510(k) first, then MDL with supplemental Canadian clinical data package. Bilingual labeling required for Canadian submission.

Audit Trail

📎 Cryptographic Provenance

US Classification → 21 CFR 862.1355 · Document hash: sha256:a4f8c2... · Effective: 2024-01-15 · Source: FDA eCFR

Canada Classification → SOR/98-282 Schedule 1 Part 2 · Document hash: sha256:b7d3e1... · Effective: 2023-09-01 · Source: Justice Laws Canada

Pathway data → 510(k) database · 40,000+ clearance records · Timeline: median 112 days (n=847 CGM submissions 2019–2024)

Models used: Pathway Navigator (classification) · Executive Synthesis (timeline) · Validator (fact-check confirmed)

Not a Chatbot Response

Every element of the answer traces back to a specific regulatory document, its effective date, and a SHA-256 hash proving exactly which version of the regulation was used. This is audit-grade regulatory intelligence, not a plausible-sounding answer.

Change Detection

If the guidance changes after your strategy is built, the system detects it. The regulatory landscape the answer was based on is recorded — so you know when that record becomes outdated.

🌐 Multi-Jurisdiction Market Access Strategy

Most device manufacturers aren't targeting one market — they're targeting several. The order in which you pursue them, and how you structure your evidence strategy, has a direct impact on total time to revenue.

🔊VO-07

🇺🇸 + 🇪🇺 US and EU

Class II US maps approximately to IIa/IIb EU MDR — but evidence requirements diverge significantly. The 510(k) substantial equivalence pathway has no direct EU equivalent. Understanding this gap early changes how you design your clinical program. MDSAP framework harmonization opportunities identified.

🇺🇸 + 🇨🇦 US and Canada

Closer alignment with opportunities to leverage FDA clearance in Health Canada submissions — but bilingual labeling requirements, different post-market surveillance obligations, and class mapping differences mean Canadian approval is never automatic.

🌍 GCC Markets

SFDA in Saudi Arabia and MOHAP in UAE accept reference to FDA or CE Mark approval in some pathways — but have their own local authorization requirements, Arabic/English documentation mandates, and local agent requirements that must be addressed independently.

Multi-Market Strategy (2–5 Jurisdictions)

MDSAP framework opportunities, IMDRF harmonization pathways, mutual recognition agreements. One integrated regulatory strategy rather than five separate ones — with sequencing recommendations that minimize total time and evidence duplication.

Harmonization Frameworks

MDSAP — Medical Device Single Audit Program

One audit accepted by FDA, Health Canada, Brazil ANVISA, Australia TGA, and Japan PMDA. MedDevicePro maps which jurisdictions accept MDSAP, what the QMS requirements are, and how MDSAP intersects with your submission strategy.

ISO 13485 + IMDRF Convergence

International harmonization pathways under IMDRF and GHTF convergence roadmaps. Where ISO 13485 certification creates leverage across multiple jurisdictions and where jurisdiction-specific QMS overlays are still required.

📡 Regulatory Change Monitoring

A change you didn't see coming can invalidate a submission strategy you spent months building. MedDevicePro monitors regulatory documents daily across all four jurisdictions and assesses the impact on your device category.

🔊VO-08

FDA Cybersecurity Guidance — June 2025

Updated requirements for connected devices: threat modeling, vulnerability disclosure program, post-market monitoring obligations, and Software Bill of Materials (SBOM). Affects every device with wireless connectivity, software, or network interfaces.

Jurisdiction: US FDA · Priority: HIGH · Effective: June 2025

EU MDR EUDAMED Transition — May 2026

Mandatory use of EUDAMED for device registration, UDI submission, and post-market surveillance reporting. Manufacturers who haven't completed EUDAMED registration by the deadline face distribution disruption in EU markets.

Jurisdiction: EU MDR · Priority: HIGH · Effective: May 2026

FDA QMSR — Quality System Regulation Reform

21 CFR Part 820 amended to align more closely with ISO 13485:2016. Manufacturers operating under the old QSR framework must assess gaps and update their QMS documentation. Design control requirements clarified.

Jurisdiction: US FDA · Priority: HIGH · Effective: February 2026

FDA AI/ML Medical Device Framework

Good Machine Learning Practice (GMLP) recommendations, dataset quality requirements, algorithm change protocols, and post-approval model monitoring obligations for AI/ML-based SaMD.

Jurisdiction: US FDA · Priority: MEDIUM · Ongoing guidance updates

Health Canada Modernization Initiatives

Ongoing updates to the Medical Devices Regulations (SOR/98-282) including post-market surveillance requirements, clinical trial authorization reforms, and fee schedule updates.

Jurisdiction: Health Canada · Priority: MEDIUM · Ongoing

GCC Harmonization Announcements

SFDA and MOHAP regulatory alignment initiatives including updated registration requirements, local authorized representative rules, and Arabic labeling standards for medical devices.

Jurisdiction: GCC (SFDA / MOHAP) · Priority: MONITOR · Ongoing

Daily Document Monitoring

Federal Register, EU Official Journal, Health Canada notices, SFDA and MOHAP announcements — monitored daily. When a document changes, the effective date is recorded and the previous version remains accessible for historical queries.

Portfolio Impact Assessment

Changes are mapped against your device category and classification. You don't get a generic regulatory alert — you get an assessment of which of your devices are affected, how, and by when.

📊 Post-Market Surveillance Requirements

Regulatory approval is not the end of the compliance story. For most jurisdictions it's the beginning of a continuous obligation — and the post-market requirements are getting more demanding, not less.

🔊VO-09

Jurisdiction	Authority	Adverse Event Reporting	Serious Incident Timeline
🇺🇸 United States	FDA MedWatch / MDR	MDR 21 CFR Part 803 — manufacturers, importers, device user facilities	30 days (serious); 5 days (imminent hazard)
🇪🇺 European Union	Notified Body / Competent Authority	MDR Article 87 vigilance system — serious incidents, field safety actions	Immediately / 15 days / 30 days (severity-dependent)
🇨🇦 Canada	Health Canada	SOR/98-282 Part 8 — mandatory problem reporting	10 days (serious injury/death); 30 days (malfunction)
🇸🇦 Saudi Arabia	SFDA	SFDA adverse event reporting requirements	Per SFDA regulation
🇦🇪 UAE	MOHAP	MOHAP vigilance requirements	Per MOHAP regulation

EU MDR PSUR Requirements

The Periodic Safety Update Report requirements for Class IIa, IIb, and III devices represent a significant ongoing documentation burden that many manufacturers underestimated when planning their MDR transition. Annual for IIb and III, every two years for IIa. Getting this right from the start is far less expensive than retrofitting it.

PMS Plan Requirements by Jurisdiction

Each jurisdiction requires a formal post-market surveillance plan as a condition of approval. MedDevicePro maps the plan requirements, the data collection obligations, and the reporting triggers — across all active jurisdictions simultaneously.

Device Registry Obligations

EUDAMED in the EU, the FDA device registration database, Health Canada's MDALL — each registry has its own UDI format requirements, update obligations, and deadline structures. Multi-jurisdiction registry management mapped in one view.

Real-World Evidence Generation

Post-market clinical follow-up requirements under EU MDR, post-approval study requirements under FDA PMA, and real-world evidence frameworks that can support future submissions or label extensions across jurisdictions.

💼 The Cost of Getting This Wrong Is Measured in Years

A rejected submission doesn't just cost the filing fee. For a Class III device, a preventable evidence gap can add 18 months to market entry. At the revenue projections most device manufacturers are working with, that's not a compliance problem — that's a business problem.

🔊VO-10

365+

days for PMA or CE Mark if evidence strategy is right

54K+

real approvals powering statistical timeline predictions

135K+

verified regulatory document chunks with crypto proof

12

submission pathways across four jurisdictions

Without MedDevicePro	With MedDevicePro	Impact
Pathway selected based on team experience with last device	Pathway eligibility mapped to this device's specific classification and attributes	Right pathway, first time
Evidence gaps discovered during FDA review	Clinical evidence gap analysis completed before submission	Gaps found early, not late
EU MDR requirements learned during Notified Body audit	MDR technical documentation requirements mapped before clinical program design	Clinical program right-sized
Regulatory guidance updates found in trade publications	Daily document monitoring with device portfolio impact assessment	No surprise changes
Multi-market strategy built independently per jurisdiction	Integrated multi-jurisdiction strategy with harmonization opportunities identified	Reduced evidence duplication
Regulatory answer backed by team's recall of guidance	Every answer includes SHA-256 hash, effective date, source URL	Audit-grade defensibility

Who Uses MedDevicePro

Medical device manufacturers building initial market access strategy. Regulatory affairs teams stress-testing submission packages before they go out. QMS executives managing post-approval change notifications. Consulting firms building defensible regulatory guidance for clients who need an audit trail.

Data Sources

80,000 chunks from FDA (21 CFR Parts 807–898, guidance documents, 510(k)/PMA databases, openFDA API). 30,000 from EU MDR/IVDR. 15,000 from Health Canada. 11,000 from GCC authorities. 5,000 from ISO 13485, ISO 14971, IEC 62304, ISO 10993.

Cryptographic Provenance on Every Answer

Every response includes the document hash, effective date, validation status, and source URL for every regulatory source used. Not because we added it afterward — because the TV-GRAG architecture requires it before a response can be generated.

Emerging Technology Coverage

Cybersecurity (June 2025 FDA guidance), Software as a Medical Device (IEC 62304, SaMD clinical validation), AI/ML devices (GMLP, algorithm change protocols, model monitoring post-approval). Coverage updates automatically as guidance evolves.

Ready to See MedDevicePro on Your Device Portfolio?

Book a personalized demo with your specific device and target markets. See the classification, pathway mapping, and evidence gap analysis in real time.